|
Real-time
Euronext Bruxelles
05:35:12 2026-09-09 am EDT
|
5-day change | 1st Jan Change | ||
| 203.70 EUR | -1.55% |
|
-7.62% | -14.63% |
| 03:27am | UCB wins 'breakthrough therapy' designation for a product |  |
| Sep. 01 | Global pharma companies that have publicly announced Trump drug pricing agreements | RE |
| Market Cap | 39.45B 45.88B 37.11B 33.87B 63.2B 4,350B 63.53B 440B 170B 2,223B 172B 169B 7,075B | P/E 2026 * |
20.7x | P/E 2027 * | 17.1x |
|---|---|---|---|---|---|
| Enterprise Value | 39.75B 46.24B 37.4B 34.13B 63.69B 4,383B 64.02B 443B 171B 2,240B 174B 170B 7,130B | EV / Sales 2026 * |
4.57x | EV / Sales 2027 * | 3.89x |
| Free-Float |
61.59% | Yield 2026 * |
0.7% | Yield 2027 * | 0.73% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Bruxelles
| UCB | Real-time | |
CBOE
| UCB | Real-time | |
|
OTC Markets
| UCBJF | Delayed | |
|
CBOE
| 0NZT | Real-time | |
|
Tradegate
| UNC | Real-time | |
|
Börse Stuttgart
| UNC | Delayed | |
|
Boerse Muenchen
| UNC | Real-time | |
|
Deutsche Boerse AG
| UNC | Delayed | |
|
London S.E.
| 0NZT | Delayed | |
|
Wiener Boerse
| UCB | End-of-day quote | |
|
Borsa Italiana
| 4UCB | End-of-day quote | |
|
Xetra
| UNC | Delayed |
Last Transcript : UCB
| 1 day | -1.55% | ||
| 1 week | -7.62% | ||
| Current month | -5.39% | ||
| 1 month | -9.51% | ||
| 3 months | -22.34% | ||
| 6 months | -20.55% | ||
| Current year | -14.63% |
| 1 week | 203.6 |  | 223.2 |
| 1 month | 203.6 | | 227.2 |
| Current year | 203.6 | | 289.5 |
| 1 year | 191.2 | | 289.5 |
| 3 years | 65.4 | | 289.5 |
| 5 years | 65.4 | | 289.5 |
| 10 years | 54.84 | | 289.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 2014-12-31 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 2020-06-30 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 2024-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 2011-12-31 | |
| Director/Board Member | 67 | 2014-12-31 | |
| Director/Board Member | 56 | 2014-04-23 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 1/15/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 1/15/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 1/15/26 | Buy | Director | 500 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.55% | -7.62% | -2.58% | +147.15% | 45.88B | |
| -2.10% | -1.64% | +45.10% | -2.45% | 80.91B | |
| -0.78% | -1.52% | -18.45% | -36.25% | 60.46B | |
| -3.59% | -9.04% | +465.16% | +30.37% | 56.02B | |
| -1.77% | -5.26% | -9.16% | +29.36% | 49.63B | |
| -3.77% | -1.64% | +50.34% | -17.95% | 31.4B | |
| -1.85% | -0.49% | +43.72% | +94.44% | 25.22B | |
| -2.00% | -3.54% | -2.68% | +156.40% | 22.25B | |
| -1.53% | -0.92% | +62.98% | +103.25% | 16.59B | |
| -3.15% | -7.97% | -24.67% | +719.34% | 14.38B | |
| Average | -2.21% | -2.11% | +60.98% | +122.36% | 40.27B | |
| Weighted average by Cap. | -2.13% | -1.64% | +77.81% | +61.75% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.69B 10.11B 8.18B 7.46B 13.93B 959B 14B 96.92B 37.5B 490B 37.97B 37.14B 1,559B | 9.68B 11.25B 9.1B 8.31B 15.5B 1,067B 15.58B 108B 41.73B 545B 42.26B 41.34B 1,735B |
| Net income | 1.93B 2.25B 1.82B 1.66B 3.09B 213B 3.11B 21.53B 8.33B 109B 8.43B 8.25B 346B | 2.32B 2.7B 2.19B 2B 3.72B 256B 3.74B 25.91B 10.03B 131B 10.15B 9.93B 417B |
| Net Debt | 306M 355M 287M 262M 490M 33.69B 492M 3.41B 1.32B 17.22B 1.33B 1.31B 54.79B | -1.81B -2.1B -1.7B -1.55B -2.9B -199B -2.91B -20.15B -7.8B -102B -7.9B -7.72B -324B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-09 | €203.70 | -1.55% | 19,188 |
| 26-09-08 | €206.90 | -1.62% | 217,397 |
| 26-09-07 | €210.30 | -0.14% | 117,305 |
| 26-09-04 | €210.60 | -4.58% | 312,911 |
| 26-09-03 | €220.70 | +0.09% | 205,856 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UCB Stock
Select your edition
All financial news and data tailored to specific country editions
